ReviewActa pharmacologica Sinica2026
Neutrophil extracellular traps in liver diseases: from molecular mechanisms to therapeutic interventions.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver diseases are hepatic pathological changes caused by a variety of pathogenic factors, including viral hepatitis, alcoholic liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis, and hepatocellular carcinoma (HCC), etc. The characteristics of liver diseases are steatosis, hepatocyte ballooning, and immune cell infiltration. Among these immune cells, neutrophils are important immune cells in innate immunity. Under hepatic pathological conditions, neutrophils can produce neutrophil extracellular traps (NETs) under the stimulation of various factors, such as viral infections, metabolic disorders, toxic exposures, etc. Accumulating evidence has shown that NETs can interact with multiple signaling pathways and immune cells, regulate hepatic inflammatory responses, remodel the hepatic immune microenvironment, and promote the activation of hepatic stellate cells (HSCs). This review expounds the mechanism of NETs in various liver diseases, and the compounds or drugs that have been discovered or applied for the treatment of liver diseases by targeting NETs. This review enriches the pathogenesis of liver diseases and provides a theoretical basis and research directions for targeted therapeutic strategies.
Indexed as
Identifiers
42754702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.